These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9274445)

  • 1. Mammographic screening for breast cancer. What cancers do we find?
    Nordén T; Thurfjell E; Hasselgren M; Lindgren A; Norgren A; Bergström R; Holmberg L
    Eur J Cancer; 1997 Apr; 33(4):624-8. PubMed ID: 9274445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age-specific effectiveness of the Nijmegen population-based breast cancer-screening program: assessment of early indicators of screening effectiveness.
    Peer PG; Holland R; Hendriks JH; Mravunac M; Verbeek AL
    J Natl Cancer Inst; 1994 Mar; 86(6):436-41. PubMed ID: 8120918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aggressiveness of breast cancers found with and without screening.
    Klemi PJ; Joensuu H; Toikkanen S; Tuominen J; Räsänen O; Tyrkkö J; Parvinen I
    BMJ; 1992 Feb; 304(6825):467-9. PubMed ID: 1547414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection method, tumour size and node metastases in breast cancers diagnosed during a trial of breast cancer screening.
    Tabar L; Duffy SW; Krusemo UB
    Eur J Cancer Clin Oncol; 1987 Jul; 23(7):959-62. PubMed ID: 3311769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using tumor phenotype, histological tumor distribution, and mammographic appearance to explain the survival differences between screen-detected and clinically detected breast cancers.
    Chuang SL; Chen SL; Yu CP; Chang KJ; Yen AM; Chiu SY; Fann JC; Tabár L; Stephen DW; Smith RA; Chen HH
    APMIS; 2014 Aug; 122(8):699-707. PubMed ID: 25046200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The comparative value of mammographic screening for women 40-49 years old versus women 50-64 years old.
    Curpen BN; Sickles EA; Sollitto RA; Ominsky SH; Galvin HB; Frankel SD
    AJR Am J Roentgenol; 1995 May; 164(5):1099-103. PubMed ID: 7717212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of the axilla in patients with screen-detected breast cancer.
    Walls J; Boggis CR; Wilson M; Asbury DL; Roberts JV; Bundred NJ; Mansel RE
    Br J Surg; 1993 Apr; 80(4):436-8. PubMed ID: 8495303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of non-sentinel node metastases in patients with symptomatic cancers compared to screen-detected breast cancers.
    Tvedskov TF; Jensen MB; Balslev E; Garne JP; Vejborg I; Christiansen P; Ejlertsen B; Kroman N
    Acta Oncol; 2016; 55(4):455-9. PubMed ID: 26452696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is the presence of mammographic comedo calcification really a prognostic factor for small screen-detected invasive breast cancers?
    James JJ; Evans AJ; Pinder SE; Macmillan RD; Wilson AR; Ellis IO
    Clin Radiol; 2003 Jan; 58(1):54-62. PubMed ID: 12565206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axillary node dissection in patients with breast cancer diagnosed through the Ontario Breast Screening Program: a need for minimally invasive techniques.
    Singhal H; O'Malley FP; Tweedie E; Stitt L; Tonkin KS
    Can J Surg; 1997 Oct; 40(5):377-82. PubMed ID: 9336528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mammographic growth rate, DNA ploidy, and S-phase fraction analysis in breast carcinoma. A prognostic evaluation in a screened population.
    Arnerlöv C; Emdin SO; Lundgren B; Roos G; Söderström J; Bjersing L; Norberg C; Angquist KA
    Cancer; 1992 Oct; 70(7):1935-42. PubMed ID: 1525769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast screening: axillary lymph node status of interval cancers by interval year.
    Bucchi L; Puliti D; Ravaioli A; Cortesi L; De Lisi V; Falcini F; Ferretti S; Frigerio A; Mangone L; Petrella M; Petrucci C; Sassoli de Bianchi P; Traina A; Tumino R; Zanetti R; Zorzi M; Paci E
    Breast; 2008 Oct; 17(5):477-83. PubMed ID: 18455401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Why did the breast cancer lymph node status distribution improve in Denmark in the pre-mammography screening period of 1978-1994?
    Rostgaard K; Vaeth M; Rootzén H; Lynge E
    Acta Oncol; 2010 Apr; 49(3):313-21. PubMed ID: 20397766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detecting which invasive cancers at mammographic screening saves lives?
    Evans AJ; Pinder SE; Burrell HC; Ellis IO; Wilson AR
    J Med Screen; 2001; 8(2):86-90. PubMed ID: 11480449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient and tumor characteristics of bilateral breast cancer at screening mammography in the Netherlands, a population-based study.
    Setz-Pels W; Duijm LE; Groenewoud JH; Louwman MW; Jansen FH; van Beek M; Plaisier ML; Voogd AC
    Breast Cancer Res Treat; 2011 Oct; 129(3):955-61. PubMed ID: 21553118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can we identify the group of small invasive (T1a,b) breast cancers with minimal risk of axillary lymph node involvement? A pathohistological and DNA flow cytometric study.
    Bezić J; Samija-Projić I; Projić P; Ljubković J; Capkun V; Tomić S
    Pathol Res Pract; 2011 Jul; 207(7):438-42. PubMed ID: 21689895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screen-detected vs clinical breast cancer: the advantage in the relative risk of lymph node metastases decreases with increasing tumour size.
    Bucchi L; Barchielli A; Ravaioli A; Federico M; De Lisi V; Ferretti S; Paci E; Vettorazzi M; Patriarca S; Frigerio A; Buiatti E;
    Br J Cancer; 2005 Jan; 92(1):156-61. PubMed ID: 15597100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of breast cancer on screening mammography allows patients to be treated with less-toxic therapy.
    Barth RJ; Gibson GR; Carney PA; Mott LA; Becher RD; Poplack SP
    AJR Am J Roentgenol; 2005 Jan; 184(1):324-9. PubMed ID: 15615996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials.
    Shen Y; Yang Y; Inoue LY; Munsell MF; Miller AB; Berry DA
    J Natl Cancer Inst; 2005 Aug; 97(16):1195-203. PubMed ID: 16106024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological differences between interval and screen-detected breast cancers diagnosed within a screening programme in Northern Portugal.
    José Bento M; Gonçalves G; Aguiar A; Antunes L; Veloso V; Rodrigues V
    J Med Screen; 2014 Jun; 21(2):104-9. PubMed ID: 24803482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.